Factor V Quebec has been described as a bleeding disorder that exhibits an autosomal dominant inheritance pattern and presents severe bleeding after trauma. Two members of a fourth-generation (IV.13 and IV.15) Canadian family have been studied in detail and are the subject of this report. Their clinical presentations and histories have been described previously (Tracy et al: J Clin lnvest 741221, 1984). Persistent abnormalities include mild thrombocytopenia and defective platelet factor V. Plasma factor V is present at near normal concentration and is fully functional. Thus, the bleeding diathesis appears to reflect the absence of platelet factor V activity. The recent report (Hayward et al: Blood 84A10a. 1994 [suppl, abstrl) of multimerin deficiency in these individuals led us to reevaluate these patients. Western blot analy-ACTOR V Quebec has been described as a bleeding F disorder that exhibits an autosomal dominant inheritance pattern and presents a severe bleeding diathesis after trauma.' Two members of a fourth-generation (IV.13 and IV. 15) Canadian family have been studied extensively. Their clinical presentations and histories were previously described.' Persistent abnormalities include mild thrombocytopenia and inactive platelet factor V. In contrast, the plasma factor V was found to be present at near normal antigen levels and was found to be fully functional after activation to factor Va. Bioassays indicated that both individuals had platelet factor V activities of less than 6% of normal while factor V antigen levels were only reduced to between 30% and 60% of normal. Thus, the bleeding diathesis appears to be associated with an absence of platelet factor V activity.
F disorder that exhibits an autosomal dominant inheritance pattern and presents a severe bleeding diathesis after trauma.' Two members of a fourth-generation (IV. 13 and IV. 15) Canadian family have been studied extensively. Their clinical presentations and histories were previously described.' Persistent abnormalities include mild thrombocytopenia and inactive platelet factor V. In contrast, the plasma factor V was found to be present at near normal antigen levels and was found to be fully functional after activation to factor Va. Bioassays indicated that both individuals had platelet factor V activities of less than 6% of normal while factor V antigen levels were only reduced to between 30% and 60% of normal. Thus, the bleeding diathesis appears to be associated with an absence of platelet factor V activity.
Human coagulation factor V circulates in plasma as a procofactor comprised of a single chain polypeptide (M, = 330,000) and is converted to an active cofactor factor Va (M, = 105,000 and M, = 74,000) following limited proteolysis by thrombin or factor Xa?*3 Factor Va binds with high affinity to platelet surfaces and functions as an essential nonenzymatic cofactor of the prothrombinase complex by combining with factor Xa to catalyze the conversion of prothrombin to thrombin. Approximately 20% of the factor V contained in the whole blood is derived from platelet agranule^^,^ and is secreted during activation by platelet agonist~.~.' When platelets are activated, factor V is released as a partially proteolyzed species, possessing significant cofactor activity.' The local release of platelet factor Va at sites of injury is presumed to increase the local concentration of factor Va, facilitating site specific hemostasis. 6 Factor V deficiencies have been previously studied by coagulation and immunologic assays to determine whether genetic defects in patients are due to abnormal molecules lacking procoagulant activity or to a decreased quantity of the molecule. Bleeding disorders involving factor V are rare, most likely because of its autosomal nature. Particular cases described have been associated with acquired inhibitors to factor V, in the form of antibodies6 Recently our laboratory studied a factor V deficient family (New Brunswick) that carried a mutant allele containing a factor V missense mutation. ' The mutation produces a factor V molecule in the ses of platelet lysates developed with a variety of monoclonal antibodies show that the a-granule proteins, fibrinogen, von Willebrand factor, factor V and osteonectin are decreased in concentration and significantly degraded in the platelets of these patients. Thrombospondin, while not degraded, is substantially decreased. In contrast. platelet factor 4 and p-thromboglobulin do not appear to be affected. These observations suggest that the a-granules are correctly assembled but the contents are subsequently subjected to proteolytic degradation. The results indicate that factor V Quebec disorder is probably associated with a generalized defect that leads to degradation of most proteins of the a-granules. plasma with reduced cofactor activity and concomitant mild parahemophilia.
Platelets contain several classes of granules in which intracellular components are sequestered. The a-granules contain and release fibrinogen,'@I3 von Willebrand factor (vWF),'"'~ ~steonectin,''*'~ thromb~spondin,'~~~~ factor V,'** platelet factor 4 (PF,), P-thromboglobulin (BTG), and platelet-derived growth Recently, factor V has been reported to be complexed with the novel protein multimerin in resting platelet lysates and to be colocalized with multimerin in platelet a -g r a n~l e s .~~ Several affected members of the factor V Quebec family have been found to be deficient in platelet multimerin?6 The combined observations raised the question of the state of the other a-granule proteins in these individuals. This report describes the status of the a granular proteins, fibrinogen, vWF, factor V, thrombospondin, osteonectin, and PF, in the two patients affected with factor V Quebec.
MATERIALS AND METHODS
Human studies. Two members of a fourth-generation (IV. 13 and IV.15) Canadian family have been studied in detail and are the subject of this report. We have described their clinical presentation and their clinical history may be found in our previous report.' These patients were restudied with their consent. Predominantly historical data show a disorder of hemostasis with an autosomal dominant inheritance pattern. Clinically this is characterized by moderate to severe bleeding after trauma, particularly dental extraction or tonsil-lectomy. Transfusion of platelets, plasma, and cryoprecipitate did not appear to ameliorate the bleeding tendency. The platelet counts indicated mild thrombocytopenia. isolation and lysis of platelets. The platelets were isolated from whole blood drawn with the two-syringe technique directly into inhibitors to prevent platelet activation. Platelets were prepared from patients and normal controls at the same time. Blood (six parts) was collected into acid-citrate dextrose anticoagulant (one part), containing 5 mmoVL EDTA, 5 pmol/L prostaglandin E, (PGE,) and protease inhibitors at the concentrations given below for the platelets lysates. All manipulations were performed at 37°C. Blood from one normal individual and two patients was drawn simultaneously. Platelets were isolated and washed to remove plasma following the method of Mustard et aLZ7 Platelet-rich plasma was obtained by centrifugation of the anticoagulated blood at 1908 for 15 minutes. Washed platelets were obtained by use of an albumin (0.35%) Tyrode's solution containing PGE, 5 pmol/L (Sigma, St Louis, MO) and heparin, 5 U/mL (Organon, Inc, West Orange, NJ) in the initial wash. After the third and final wash, the platelets were resuspended in Tyrode's medium wash, 5 mmol/L HEPES, without albumin, pH 7.4. The platelets were counted with a Technicon HI counter (Technicon, F'uerto Rico) and adjusted to a final concentration of 1 X 109/mL. The Tyrode's HEPES solution was removed by centrifugation, and the platelets were lysed by replacing the Tyrode's HEPES solution with an identical volume containing 0.5% Triton X-100 20 mmollL HBS, 100 mmolR. NaC1, pH 7.4 and the following protease inhibitors: 10 mmol/L EDTA, 0.02 mg/mL soybean trypsin inhibitor, 0.1 pmom leupeptin, 0.2 mm phenylmethysulfonyl fluoride (PMSF). The platelet lysates, I X 10' plateletslml, were frozen on dry ice. All experiments were carried out in parallel on the normal and the two patients.
Human factor V was prepared from fresh frozen human plasma using immunoaffinity chromatography as described previously.28 Factor Va was prepared by the incubation of factor V with catalytic amounts of thrombin (1.5 U/mL).*.' Fibrinogen and platelet factor 4 were gifts from Haematologic Technologies, Inc (Essex Junction, VT). Human platelet osteonectin was isolated from thrombin-activated platelets as described by Kelm and Mann.'* Human thrombospondin was prepared from the supernatant of activated platelets by heparin-agarose affinity chromatography and gel filtration.'" vWF was a gift from Dr D. Meyer (H. Bicetre, Paris, France)." A monoclonal antibody (MoAb) against the heavy chain of human factor VNa, a-HFV-17, an MoAb that recognizes the light chain of factor Va a-HFV-9;' and an MoAb recognizing the a-chain of human fibrinogen aFng-3A, were obtained from Dr W.R. Church (Department of Biochemistry, University of Vermont College of Medicine). An anti-osteonectin MoAb, IIIAiAx was prepared in the laboratory as described by Stenner et An MoAb to thrombospondin, P10 a-TSP, was obtained from AMAC Inc (Westbrook, ME). Burro antihuman platelet factor 4 (PF4) IgG was prepared in our laboratory by Dr M. Rand as described" and an MoAb against vWF, a-vWF-495, was a gift from Dr D. Meyer. Bioassays of platelet factor V were previously r e p~r t e d .~ Radioimmunoassay of factor V were performed as previously de~cribed.~.~ Densitometry was accomplished with a Microscan loo0 scanning densitometer (Tri Inc, Nashville, TN). Radioimmunoassays of pthromboglobulin were performed in the Laboratory for Clinical Biochemistry Research, University of Vermont.
Gel electrophoresis and Westem blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analyses were performed using 4% to 12% and 8% to 20% gradient gels according to the method of Laemmli.'* The proteins were transferred to nitrocellulose membranes (Trans-Blot nitrocellulose; Bio-Rad, Hercules, CA) using a previously described method." The nonspecific sites of the membranes were blocked by the addition of 5% nonfat milk Proteins, antibodies, and assays.
(Carnation Co, Los Angeles, CA) (wtlvol) in TBSmween for 1 hour at room temperature followed by incubation with usually a purified MoAb. The final concentration of the antibodies varied from 1 to 5 pg/mL, depending on the antibody used. After another wash in TBS/ Tween, the nitrocellulose membrane was incubated with conjugated goat-antimouse horseradish peroxidase IgG (Southern Biotechnology Associates, Inc, Birmingham, AL) at 1:5,OOO dilution. The peptide fragments were detected using the chemiluminescent Luminol Developer (ECL Westem blotting detection system; Amersham Corp, Arlington Heights, IL).
RESULTS
Factor VNa. The platelet factor V was analyzed by Western blots using two MoAbs, one that recognizes the heavy chain as shown in Fig 1A and the other the light chain, Fig 1B. Comparable amounts of platelets of a normal individual and two patients were placed on the 4% to 12% SDS-PAGE gels. In all samples from patient IV. 13 (lanes 9 through 12), and patient IV.15 (lanes 13 and 14), factor V is much decreased when compared with the normal (lanes 5 through 8). It is apparent that platelet factor V from the patients (lanes 9 through 14) is degraded and results in many fragments different from those observed in the normal (lanes 5 through 8). Normal activation of platelet factor V with thrombin results in fragments M, = 150,000 and M, = 74,000 associated with the light chain, and M, = 105,000 and M, = 71,000 associated with the heavy chain. Fractions of the platelet lysates were treated with thrombin (+IIa), 5 U/mL, 5 minutes 37"C, a high concentration to overcome the protease inhibitors. In both immunoblots, lanes 7 and 8 represent the normal with thrombin added, and lanes 11, 12, and 14 represent patients IV.13 and IV.15 with thrombin. In both immunoblots, we see little, if any, change of factor V N a in the lanes of the patients after thrombin addition. The components expected after thrombin activation, especially the M, = 150,000 light chain precursor and the M, = 105,000 heavy chain are for all practical purpose missing in the patients. We also observe that the platelet factor V of the patients is proteolyzed to discrete fragments (ie, M, = 45,000 to 35,000), and shows a pattern of proteolysis different from the normal. The results of these Western blots show that factor V is decreased and degraded in the platelet lysates of these patients when compared with the normal.
The factor V in the plasma of the patients and the normal controls were also analyzed using the two MoAbs to the factor Va heavy and light chains. The results (data not shown) indicate that no difference in factor V or factor Va was found quantitatively or qualitatively in the platelet-poor plasma of the patients as compared with the normal and upon activation by thrombin the expected fragments were obtained. These results confirm our previous observation that indicated that plasma factor V in the patients is normal and functional.
vWF. vWF is normally present in both plasma and platelets and is composed of a series of high-molecular-weight multimers that range between M, 0.5 to 10 X 109.'5,'6 When the disulfide bonds are reduced with P-mercaptoethanol, a single predominant band is seen on SDS-PAGE with an apparent molecular weight of M, = 270,000. The platelets lysates were analyzed on a 3% to 15% SDS-PAGE gel under reducing conditions. The immunoblots were developed with a primary MoAb against vWF as described in Materials and Methods. In Fig 2A, comparable amounts of platelets from the normal, lanes 4 and 5, and the two patients, lanes 6 and 7, patient IV. 13, and lane 8, patient IV.15, were run in parallel on the gel. The results indicate that the total vWF factor antigen levels (intact plus fragments) are not substantially decreased but the molecule is degraded in both patients when compared with the normal and the fragments are similar in both patients.
Osteonectin is a noncollagenous bone protein that is also contained and secreted from human platelets on activation with thrombin or collagen." Purified platelet osteonectin is a single-chain molecule that exhibits a slightly larger apparent molecular weight (39,000) than that of osteonectin from bone.'' Osteonectin immunoblot analyses us-
Osteonectin.
ing MoAb IIIA3A, are shown in Fig 2B. The platelets lysates were analyzed on a 3% to 15% SDS-PAGE gel under reducing conditions. The samples in lanes 4 through 8 are identical to those in Fig 2A. The immunoblots show that in the patients' platelet lysates, osteonectin is degraded when compared with the normal and shows a distinctive pattern of degradation in both patients.
Thrombospondin is a glycoprotein released from the a-granules of stimulated platelets, which appears to play a role in platelet aggregation by stabilizing the plate1et:fibrinogen interaction.'0~2" The apparent molecular weight of the protein, M, = 540,000. is decreased under reducing conditions to M, = 170,000. The platelet lysates were run on a 4 8 to 12% SDS-PAGE gel under reducing conditions. The immunoblot was developed with the MoAb PI0 a-TSP and is shown in Fig 3A. Comparable amounts
Thromhospondin.
For personal use only. on April 11, 2017. by guest www.bloodjournal.org From of platelets of a normal individual, lanes 3 and 4, and the two patients lanes 5 and 6, patient IV.13, and lane 7, patient IV.15, were run in parallel. Thrombospondin is substantially decreased in the platelet lysates of both patients when compared with the normal. It is not known if thrombospondin is degraded, but the MoAb did not reveal any fragments. Fibrinogen. Fibrinogen is present in the a-granules of platelets, where it normally constitutes 4% to tions. The results indicate that fibrinogen is present at decreased concentration and is degraded in the two patients (lanes 8 through 1 1 in Fig 4A and lanes 8 through 13 in Fig  4B) , when compared with two normals (lanes 4 and 5, and 6 and 7, Fig 4A and B) .
PF, is a low-molecular-weight heparin-binding protein that is secreted f " agonist-activated platelets2' and is localized within the a-granules where its concentration normally ranges from 11.2 to 12.4 ygll X lo9 platelets. On a molar basis, PF, is one of the most abundant proteins in the platelets. The platelet factor 4 monomer has a molecular weight of M, = 7,800. In its native state, PF, is a homotetramer that complexes with a high-molecular-weight proteoglycan carrier protein. The results of the Westem blots analyses of PF4 are shown in Fig 3B. Comparable amounts of the platelets were run on an 8% to 20% SDS-PAGE gel, followed by immunoblotting with a polyclonal antibody to PF,. The platelets of the normal are in lanes 5 and 6, those of patient IV.13 in lane 7 and 8, and patient IV.15 in lane 9. By densitometry and comparison with purified human PF4, the normal platelet lysate was calculated to contain 15.2 ygll X IO9 platelets PF,, whereas those of the patients were, respectively, 122% and 113% of this value. In this case we attempted to calculate a concentration for the PF4 because the protein is not degraded into fragments. P-Thromboglobulin was assayed by radioimmunoassay and found to be at normal levels in both patients (data not shown).
We speculate that either there is a gross packaging and/or storage defect of proteins in the a-granules or that these proteins are degraded by a specific protease in the platelets. These results indicate that factor V Quebec disorder is probably associated with a generalized defect which leads to degradation of most proteins of the a-granules. These findings likely have a direct bearing on the severity of the symptoms in these patients.
For 
DISCUSSION
The index family exhibits a serious bleeding disorder previously attributed to the presence of inactive platelet factor VNa.' In that study a gross discrepancy was observed between the amount of platelet associated factor V determined by either bioassay or radioimmunoassay (RIA) for both patients. In the case of patient IV.13, the RIA indicated nearnormal level of antigen; however, only 2% of the molecules expressed FVa activity after thrombin activation. In the case of patient IV.15, the platelet factor V antigen was reduced and only 4% of the factor V present expressed cofactor activity. The only functional abnormality observed was inactive platelet factor V. Thus, a more general defect in the ability of the platelets to support coagulation was not suspected. ' Subsequently, Hayward et al" investigated the same individuals using a multimerin assay. They had identified multimerin as a complex multimeric protein that is stored within platelet a-granules and endothelial cell Weibel-Palade bodies.25 Because it also appears to be a factor V binding protein, Hayward et alZs have suggested that multimerin plays a role in the storage of factor V within platelet a- granules. Using an enzyme-linked immunosorbent assay (ELISA), platelets from three afflicted members of the index family, including patients IV.13 and IV.15. were found to be deficient in platelet multimerin. with values ranging from 0.09 to 0.16 U/I X IO9 platelets (normal range. 0.5 to 2.0 U/I X 10" platelets). Multimer analyses identified only the smallest multimers of multimerin in the platelet lysates of the affected family members. Two unaffected family members had normal multimerin levels. These investigators also reported that the level of several other a-granular proteins. including P-thromboglobulin and vWF were normal in both afflicted and nonafflicted family members. Recently. the same investigators reported a multimerin deficiency in a second Quebec family with an autosomal bleeding disorder. with no relations common to the factor V Quebec pedigree." Platelet factor V antigen levels. evaluated using the ELISA assay and polyclonal antisera, were also reduced (20%: normal range. 48% to 148%). These observations led us to reinvestigate the factor V levels in the affected siblings and extend our analyses to other a-granule proteins. In the present study we have obtained evidence that factor V and multimerin are not the only altered proteins present in the platelet a-granules of these patients. With the exception of PF, and P-thromboglobulin, all of the a-granule proteins analyzed, factor V, fibrinogen, vWF, thrombospondin. and osteonectin, were either degraded or were present at decreased levels. Thrombospondin is very much decreased in the patients, although we do not have any evidence that is degraded. However, there is always the possibility that the MoAb would not recognize the fragments. For the same reason we have not attempted to calculate total protein content from the immunoblots when the protein is degraded. Fibrinogen also show a large decrease in the a-granules of the Quebec patients. Table I Table 1 ). Thus, the amount of these two proteins represents the concentration of the total protein as total antigen in the platelet lysate. Multimerin is represented as the average of the range given in unitdl x 10' platelets as reported?6
For personal use only. on April 11, 2017. by guest www.bloodjournal.org From Hayward et alZ6 on the same patients. The results of the radioimmunoassays indicate that factor V antigen is present at a decreased level in the platelet lysates of the two patients compared with the normal. Multimerin, given as a range, is also decreased in the affected individuals. These assays represent total protein concentrations. We observe from Table l that the decrease in multimerin does not correlate well with factor V. As observed in Table 1 for the patients, the decrease in multimerin varies between 4.5% and 32% whereas that of factor V varies between 30% and 65%. This could indicate that multimerin deficiency is not necessarily associated with factor V as has been sugge~ted?~ but may be just another macromolecule that is altered in these patients.
A composite display of the intact proteins present in the affected individuals is shown in Fig 5. The immunoblots were subjected to densitometry and only the intact protein is represented here as explained in the legend of Fig 5. Thus, the decreases seen in Fig 5 represent the loss of the intact protein only. In contrast, the RIA and ELISA results for factor V and multimerin represent the quantities of the total antigen concentrations of these proteins.
Immunoassay quantitation of plasma and platelet proteins yields a result that reflect total protein and peptide content without necessarily distinguishing between intact and degraded proteins. However, immunoblotting analysis has the advantage of allowing for the visualization of degradation products and thus is a more complete and accurate analysis of the status of the proteins. In view of our results, which show that more than one protein of the a-granules may be altered, a reassessment of the disorder in these patients is necessary. We have shown in a previous paper that human platelet factor V is released as a partially proteolyzed species possessing cofactor activity in the prothrombinase complex.' All attempts so far to isolate human platelet factor V as a single-chain procofactor in platelet lysates have failed,5 and thus it is probable that factor V is stored in platelets as a partially proteolyzed cofactor.' Our present results, visible on the immunoblots in Fig 1 lanes 5 and 6, for the factor V of the normal individual attest to these findings. In this report we speculate that another protease is responsible for the degradation observed of factor V and of the other macromolecules in the a-granules of the patients. Calpain, a calciumdependent protease present in platelets is a likely candidate. Bradford et a135 reported that purified platelet calpain cleaves human factor V and the cleavage pattern reported by Viskup et a15 from our laboratory may have similarities to that of calpain cleaved factor V. Calpain has also been reported to cleave vWF, fibrinogen, and cytoskeletal protein^.^^.^^ An increase in the concentration or the activity of this enzyme or the absence of its suppressor could be responsible for the degradation observed on the a-granule proteins in the Quebec patients.
A second possibility is that there is a defect in the storage and packaging mechanism of the a-granules of these patients that would affect all these proteins. Inherited abnormalities of platelet a-granules have been de~cribed.~' Studies of patients with the rare condition Gray platelet syndrome have shed light on the chemical content localized within the different types of a-granules. In the Gray platelet syndrome, platelets are virtually devoid of a-granules and are deficient in products confined to these organelles, including PF4 and pthromboglob~lin.~' The presence of normal levels of intact PF4 and BTG suggest that the a-granule is assembled normally in factor V Quebec.
